DUETRE Trademark

Trademark Overview


On Wednesday, November 8, 2017, a trademark application was filed for DUETRE with the United States Patent and Trademark Office. The USPTO has given the DUETRE trademark a serial number of 87676275. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 10, 2021. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The DUETRE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharm...
duetre

General Information


Serial Number87676275
Word MarkDUETRE
Filing DateWednesday, November 8, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 10, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 12, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 17, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, May 10, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 10, 2021ABANDONMENT - NO USE STATEMENT FILED
Saturday, October 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 1, 2020EXTENSION 3 GRANTED
Thursday, October 1, 2020EXTENSION 3 FILED
Thursday, October 1, 2020TEAS EXTENSION RECEIVED
Wednesday, April 8, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 6, 2020EXTENSION 2 GRANTED
Monday, April 6, 2020EXTENSION 2 FILED
Monday, April 6, 2020TEAS EXTENSION RECEIVED
Tuesday, October 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 4, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 4, 2019EXTENSION 1 GRANTED
Friday, October 4, 2019EXTENSION 1 FILED
Friday, October 4, 2019TEAS EXTENSION RECEIVED
Tuesday, April 9, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 14, 2018EXAMINER'S AMENDMENT ENTERED
Friday, December 14, 2018NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, December 14, 2018EXAMINERS AMENDMENT E-MAILED
Friday, December 14, 2018EXAMINERS AMENDMENT -WRITTEN
Wednesday, December 12, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 12, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 12, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 8, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 8, 2018NON-FINAL ACTION E-MAILED
Wednesday, August 8, 2018NON-FINAL ACTION WRITTEN
Thursday, July 26, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 26, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 26, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 21, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 21, 2018NON-FINAL ACTION E-MAILED
Wednesday, February 21, 2018NON-FINAL ACTION WRITTEN
Wednesday, February 21, 2018ASSIGNED TO EXAMINER
Friday, November 17, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, November 11, 2017NEW APPLICATION ENTERED IN TRAM